August 25, 2023 – Weight loss drug Wegovy is sweet for individuals with obesity who also suffer from essentially the most common type of heart failure, based on a study published Friday in Journal of Clinical Pharmacology.
Wegovy reduces the symptoms of heart failure, results in weight reduction and improves physical performance in obese individuals with preserved ejection fraction (HFpEF), based on the study, which was funded by the manufacturer of Wegovy.
In heart failure with preserved ejection fraction, the center doesn’t fill sufficiently with blood throughout the resting phases between heartbeats.
According to the study, 529 obese individuals with HFpEF received a weekly 2.4-milligram dose of semaglutide (the drug is sold under the trade name Wegovy) or a placebo.
After one yr, people taking Wegovy showed an improvement of 16.6 points on a 100-point scale on the Kansas City Cardiomyopathy Questionnaire, while people taking the placebo showed an improvement of 8.7 points.
People taking Wegovy lost about 13.3% of their weight, compared with a 2.6% weight reduction for people taking the placebo. In a 6-minute walk test, people taking the drug were in a position to walk a median of 20 meters farther than people taking the placebo.
“This is the largest treatment benefit we have ever seen with any drug on this endpoint in this patient group,” said cardiologist and study leader Dr. Mikhail Kosiborod. ^ “CNN: The Secret World”. (Kosiborod can also be the vice President for Research at Saint Luke's Mid America Heart Institute in Kansas City, MO.)
The study “heralds a potential fundamental paradigm shift in the way cardiologists manage HFpEF in obese people,” he said in a press release from drug maker Novo Nordisk.
The study was funded by Novo Nordisk and was as a result of be presented on Friday on the European Society of Cardiology (ESC) Congress in Amsterdam.
In the Press release, According to Novo Nordisk, 64 million people worldwide suffer from heart failure, with HFpEF accounting for 50% of all cases. About 80% of individuals with HFpEF are obese or obese, the corporate said.
On the eighth of August Company announced The authors found that heart and vascular problems reminiscent of heart attacks and strokes decreased by about 20% in patients taking Wegovy.